These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38640639)

  • 41. PCV2 vaccination induces IFN-γ/TNF-α co-producing T cells with a potential role in protection.
    Koinig HC; Talker SC; Stadler M; Ladinig A; Graage R; Ritzmann M; Hennig-Pauka I; Gerner W; Saalmüller A
    Vet Res; 2015 Mar; 46():20. PubMed ID: 25888899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immunogenicity of a recombinant pseudorabies virus coexpressing ORF2 gene of PCV2 and porcine IL-18 gene in mice].
    Guo X; Zhu Q; Pan X; Yang X; Qiao H; Wang S; Chen H
    Wei Sheng Wu Xue Bao; 2016 Jan; 56(1):120-9. PubMed ID: 27305786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the efficacy of a novel porcine circovirus type 2 synthetic peptide vaccine.
    Jeong J; Park C; Kim S; Park SJ; Kang I; Park KH; Chae C
    Can J Vet Res; 2018 Apr; 82(2):146-153. PubMed ID: 29755195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model.
    Fort M; Sibila M; Pérez-Martín E; Nofrarías M; Mateu E; Segalés J
    Vaccine; 2009 Jun; 27(30):4031-7. PubMed ID: 19379787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimized production of full-length PCV2d virus-like particles in Escherichia coli: A cost-effective and high-yield approach for potential vaccine antigen development.
    Zhang C; He F; Li N; Du W; Wen J; Wu X; Shi J; Li C; Liu C; Xu S; Han H; Hrabchenko N; Han X; Li J
    Microb Pathog; 2024 May; 190():106630. PubMed ID: 38556102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coli.
    Wu PC; Chen TY; Chi JN; Chien MS; Huang C
    J Biotechnol; 2016 Feb; 220():78-85. PubMed ID: 26795354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction and immunogenicity of a recombinant pseudorabies virus co-expressing porcine circovirus type 2 capsid protein and interleukin 18.
    Zheng LL; Guo XQ; Zhu QL; Chao AJ; Fu PF; Wei ZY; Wang SJ; Chen HY; Cui BA
    Virus Res; 2015 Apr; 201():8-15. PubMed ID: 25701744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination.
    Aravindaram K; Kuo TY; Lan CW; Yu HH; Wang PH; Chen YS; Chen GH; Yang NS
    J Gene Med; 2009 Apr; 11(4):288-301. PubMed ID: 19194994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune responses and vaccine-induced immunity against Porcine circovirus type 2.
    Kekarainen T; McCullough K; Fort M; Fossum C; Segalés J; Allan GM
    Vet Immunol Immunopathol; 2010 Aug; 136(3-4):185-93. PubMed ID: 20451259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptides mimicking viral proteins of porcine circovirus type 2 were profiled by the spectrum of mouse anti-PCV2 antibodies.
    Hung LC; Yang CY; Cheng IC
    BMC Immunol; 2017 May; 18(1):25. PubMed ID: 28506209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The composite biological adjuvants enhance immune response of porcine circovirus type2 vaccine.
    Guo X; Zheng Q; Jiang X; Wu C; Zhang T; Wang D; Wang X; Liu T; Wang N; Jiang Y; Li D; Ren G
    Vet Microbiol; 2019 Jan; 228():69-76. PubMed ID: 30593382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.
    Seo HW; Oh Y; Han K; Park C; Chae C
    BMC Vet Res; 2012 Oct; 8():194. PubMed ID: 23078878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant Orf virus induced antibody production against capsid protein of porcine circovirus type 3 in mice.
    Gao K; Li H; Lei X; Sun Z; Zheng T; Chen M; Ning Z
    Vet Res Commun; 2023 Dec; 47(4):2071-2081. PubMed ID: 37421550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of an effect of a commercial vaccine adjuvant on the development of postweaning multisystemic wasting syndrome (PMWS) in porcine circovirus type 2 (PCV2) experimentally infected conventional pigs.
    Resendes A; Segalés J; Balasch M; Calsamiglia M; Sibila M; Ellerbrok H; Mateu E; Plana-Durán J; Mankertz A; Domingo M
    Vet Res; 2004; 35(1):83-90. PubMed ID: 15099505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chitosan microparticles loaded with yeast-derived PCV2 virus-like particles elicit antigen-specific cellular immune response in mice after oral administration.
    Bucarey SA; Pujol M; Poblete J; Nuñez I; Tapia CV; Neira-Carrillo A; Martinez J; Bassa O
    Virol J; 2014 Aug; 11():149. PubMed ID: 25141864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Baculovirus expression of the N-terminus of porcine heat shock protein Gp96 improves the immunogenicity of recombinant PCV2 capsid protein.
    Zhu X; Liu J; Bai J; Liu P; Zhang T; Jiang P; Wang X
    J Virol Methods; 2016 Apr; 230():36-44. PubMed ID: 26826323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of a recombinant pseudorabies virus expressing ORF1-ORF2 fusion protein of porcine circovirus type 2.
    Ju C; Fan H; Tan Y; Liu Z; Xi X; Cao S; Wu B; Chen H
    Vet Microbiol; 2005 Aug; 109(3-4):179-90. PubMed ID: 16006077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Production of Escherichia coli-based virus-like particle vaccine against porcine circovirus type 2 challenge in piglets: Structure characterization and protective efficacy validation.
    Xi X; Mo X; Xiao Y; Yin B; Lv C; Wang Y; Sun Z; Yang Q; Yao Y; Xuan Y; Li X; Yuan YA; Tian K
    J Biotechnol; 2016 Apr; 223():8-12. PubMed ID: 26907669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and Immunoprotection of PCV2 Virus-like Particles Incorporating Dominant T and B Cell Antigenic Epitopes Paired with CD154 Molecules in Piglets and Mice.
    Wu K; Hu W; Zhou B; Li B; Li X; Yan Q; Chen W; Li Y; Ding H; Zhao M; Fan S; Yi L; Chen J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.
    Ding P; Jin Q; Chen X; Yang S; Guo J; Xing G; Deng R; Wang A; Zhang G
    Int J Nanomedicine; 2019; 14():7533-7548. PubMed ID: 31571862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.